Company news
Uniqure N.v. (NASDAQ:QURE) news
Every Uniqure N.v. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
UniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
July 29, 2026
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
July 29, 2026
UniQure to Announce Second Quarter 2026 Financial Results
July 22, 2026
uniQure to Announce Second Quarter 2026 Financial Results
July 22, 2026
UniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
June 25, 2026
UniQure Announces Pricing of Upsized $225 Million Public Offering
June 23, 2026
uniQure Announces Pricing of Upsized $225 Million Public Offering
June 23, 2026
UniQure Announces $150 Million Proposed Public Offering
June 22, 2026
uniQure Announces $150 Million Proposed Public Offering
June 22, 2026
UniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Ep...
June 19, 2026
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Ep...
June 19, 2026
UniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
June 17, 2026
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
June 17, 2026
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
May 5, 2026
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
April 30, 2026
uniQure to Announce First Quarter 2026 Financial Results
April 28, 2026
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
March 2, 2026
uniQure to Announce 2025 Financial Results
February 23, 2026
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fa...
February 6, 2026
uniQure Announces Type A Meeting Scheduled with FDA
January 9, 2026
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
December 4, 2025
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
uniQure to Announce Third Quarter 2025 Financial Results
November 6, 2025
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
September 29, 2025
uniQure Announces Pricing of Upsized $300 Million Public Offering
September 25, 2025
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
September 24, 2025
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
September 24, 2025
uniQure Announces $200 Million Proposed Public Offering
September 24, 2025
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
September 5, 2025
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
July 29, 2025
uniQure to Announce Second Quarter 2025 Financial Results
July 22, 2025
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
June 11, 2025
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
May 29, 2025
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
May 19, 2025
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
May 9, 2025
uniQure to Announce First Quarter 2025 Financial Results
May 5, 2025
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
April 17, 2025
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
February 27, 2025
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committe...
February 3, 2025
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-16...
January 30, 2025
uniQure Announces Pricing of its Public Offering
January 8, 2025
uniQure Announces Proposed Public Offering
January 7, 2025
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
December 10, 2024
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal...
November 21, 2024
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
November 5, 2024
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
October 15, 2024
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
September 23, 2024
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
August 15, 2024
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
August 1, 2024
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
July 23, 2024